Author of

• 36336

  +

  P76 - Targeted Therapy - Clinically Focused - EGFR (ID 253)

  • Event: WCLC 2020
  • Type: Posters
  • Track: Targeted Therapy - Clinically Focused
  • Presentations: 1
  • Moderators:
  • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall

  • 36366

    +

    P76.26 - Survival Outcomes in Patients Receiving Second Line Osimertinib Post First Line First Generation TKI Alone or in Combination with Chemotherapy (ID 1372)

    00:00 - 00:00  |  Presenting Author(s): Satvik Khaddar
    • Abstract
    • Slides

    Introduction
    

    Although osimertinib is recommended as first line therapy in patients with EGFR mutated NSCLC, the cost and limited availability in developing countries prohibits its widespread use. Osimertinib is the standard of care second line anti EGFR therapy in non small cell lung cancer (NSCLC) who develop exon 20 T790M mutation post progression on first generation TKI. With recent evidence of efficacy of first generation TKI plus chemotherapy combination as effective first line therapy in EGFR mutated NSCLC, it is not known whether second line osimertinib leads to different outcome.

    Methods
    

    We retrospectively analysed data of patients from the study of gefitinib (Gef) vs gefitinib plus chemotherapy (GC) who progressed after first line therapy and were found to harbour exon 20 T790M mutation in repeat biopsy or cell free DNA samples and received Osimertinib as second line therapy. We compared progression free survival (PFS) and overall survival (OS) on 2nd line Osimertinib in patients who received Gefitinib versus Gefitinib plus Pemetrexed Carboplatin as 1st line chemotherapy.

    Results
    

    A total of 65 patients received osimertinib in the second line settings out of which 58 were analysable. There were 30 males and 28 females. The median age of cohort was 53 years (range 38-72). The median followup duration was 10 months. Median PFS on osimertinib in patients who received Gef (n=35) as first line therapy was 9 months (95% CI: 5.5-12.5) while for patients of GC arm, it was 8 months (95% CI: 4.8-11.2), p=0.483.. The corresponding median OS was 12 months (95% CI: 8.1-15.9) and 17 months (95% CI: 5.5-28.5), p=0.353.

    Conclusion
    

    There was no statistically significant difference between PFS and OS on second line osimertinib for patients who received first line first generation TKI alone or in combination with chemotherapy.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.